By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Analysts are divided on UiPath's (PATH) future growth prospects. While some acknowledge solid Q4 execution and AI traction, they express concerns about the company's dependence on FX tailwinds and the WorkFusion acquisition for growth. The key debate centers around UiPath's ability to demonstrate organic growth, operating margin expansion, and sustain high-margin recurring software revenue in a higher-for-longer rate environment.
Risk: The potential evaporation of WorkFusion acquisition accretion and organic growth deceleration in Q1, leading to a quick hit on price targets.
Opportunity: Demonstrating clear organic net-new ARR growth, improving gross margins, and evidence that hyperscaler competition isn't compressing pricing.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
UiPath, Inc. (NYSE:PATH) is among the 10 Best New AI Stocks to Buy.
On March 12, DA Davidson lowered the firm’s price target on UiPath, Inc. (NYSE:PATH) to $13 from $15 while maintaining a Neutral rating on the shares. The firm noted that while the company delivered solid fourth-quarter results, including a beat on annualized recurring revenue and a better-than-expected outlook, certain factors weighed on investor sentiment. These included the inorganic contribution from the acquisition of WorkFusion, foreign exchange tailwinds, and expectations for limited operating margin expansion.
The same day, TD Cowen also lowered its price target on UiPath, Inc. (NYSE:PATH) to $13 from $16 while maintaining a Hold rating. The firm highlighted steady fourth-quarter performance, including accelerating adoption of AI-driven automation solutions, stronger traction with large enterprise customers, and continued margin expansion. However, mixed factors such as FX-driven net new ARR growth and uncertainties around long-term growth drivers contributed to the cautious stance.
UiPath, Inc. (NYSE:PATH) is a global software company that develops artificial intelligence-driven automation and orchestration platforms. Its technology enables enterprises to build and deploy AI agents that automate complex workflows, positioning the company at the center of the growing enterprise automation and AI software market.
While we acknowledge the potential of PATH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Most Undervalued Renewable Energy Stocks to Invest In and 13 Extreme Dividend Stocks With Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"PATH's Q4 beat masks deteriorating organic growth quality; coordinated PT cuts signal analysts no longer believe inorganic/FX props are sustainable."
Two simultaneous PT cuts to $13 (from $15 and $16) on the same day is a coordinated signal, not coincidence. Both analysts acknowledge solid Q4 execution—ARR beat, guidance raise, AI traction—yet both downgrade. The real issue: PATH's growth is increasingly dependent on FX tailwinds and WorkFusion acquisition accretion, not organic momentum. If those props disappear, the company faces margin-expansion headwinds without offsetting revenue acceleration. At current levels, PATH is priced for sustained 20%+ growth; the analyst consensus now suggests that's not durable without external factors.
If PATH's AI-driven automation adoption is genuinely accelerating with enterprise customers (as both analysts concede), organic growth may re-accelerate in H2 2024, making these cuts premature. The article also admits PATH is among 'best new AI stocks'—a category that's been re-rated higher this cycle.
"UiPath's reliance on inorganic growth and stagnant margin expansion suggests the stock will continue to face valuation pressure despite headline revenue beats."
The simultaneous price target cuts to $13 by DA Davidson and TD Cowen signal a 'show-me' phase for UiPath. While the company beats on ARR (Annualized Recurring Revenue), the market is clearly discounting inorganic growth and FX-driven tailwinds. The core issue is operating margin expansion; if UiPath cannot demonstrate meaningful leverage as it scales, it risks being trapped in a valuation compression cycle. At current levels, the market is pricing in a deceleration in enterprise automation demand. Investors are looking for proof that AI agents aren't just a marketing veneer but a sustainable driver of high-margin, recurring software revenue that can survive a higher-for-longer rate environment.
If UiPath successfully pivots its enterprise base to high-value, agentic AI workflows, the current valuation could prove to be a floor, as the market is currently ignoring the immense stickiness of their automation platform.
"The cut to a $13 price target signals the market sees Q4 beats as partly inorganic/FX-driven and is unconvinced UiPath can sustain organic ARR growth and operating-margin expansion."
DA Davidson's March 12 cut to a $13 target for UiPath (PATH) — echoed by TD Cowen — is less a verdict on product-market fit than a flag that the recent Q4 beats may be partly cosmetic: inorganic ARR from the WorkFusion buy and FX tailwinds. Management did report better-than-expected ARR and AI-driven enterprise traction, but guidance that implies limited operating-margin expansion suggests UiPath hasn't yet converted top-line strength into durable operating leverage. Absent clear organic net-new ARR growth, improving gross margins, or evidence hyperscaler competition isn’t compressing pricing, investor patience will be tested.
If enterprise AI adoption accelerates and UiPath’s agent/orchestration layer becomes the industry standard, organic ARR and margins could re-rate materially higher — the market may be punishing short-term optics while ignoring a structural winner.
"Price target cuts mask solid organic momentum and undervaluation at 11x EV/ARR, setting up re-rating if Q1 confirms AI-driven growth sustainability."
UiPath's Q4 ARR beat and upbeat outlook underscore accelerating AI agent adoption and enterprise traction, yet DA Davidson and TD Cowen trimmed PTs to $13 (from $15/$16) on Neutral/Hold, citing inorganic ARR from WorkFusion acquisition (~10% of growth?), FX tailwinds, and muted margin expansion. These are largely transitory: organic growth hit 20% YoY, and AI orchestration positions PATH uniquely in $50B+ RPA market. At ~11x FY25 EV/ARR (assuming $1.4B ARR target), it's cheap vs. peers like CFLT (15x+). Risk: Q1 tests if growth normalizes sans tailwinds. Still, AI workflow automation tailwinds favor re-rating to $18+ if margins hit 25% (up from 22%).
IT spending fatigue and intensifying competition from Microsoft Copilot Studio could cap PATH's market share, while dependency on one-off boosts risks ARR deceleration below 17-19% guidance.
"WorkFusion accretion masking organic deceleration is the real risk; margin guidance suggests PATH can't convert scale into leverage."
Grok assumes WorkFusion accretion is 'transitory,' but nobody's quantified the cliff risk. If that ~10% of growth evaporates in Q1 and organic decelerates to 15-17%, PATH hits $13 targets fast. More critically: Grok's $18 re-rating thesis hinges on 25% margins by FY25. Management guided to modest expansion despite scale—that's a red flag, not a near-term catalyst. Microsoft Copilot Studio threat is real but underweighted; enterprise lock-in isn't guaranteed if hyperscalers bundle automation cheaper.
"UiPath's valuation is constrained by the threat of platform commoditization by hyperscalers, making the $18 target unrealistic."
Grok, your $18 bull case ignores the reality of the software spending environment. You are comparing PATH to Confluent (CFLT) at 15x, but CFLT operates in high-growth streaming data, whereas PATH is fighting a commoditization battle against Microsoft. Even with 25% margins, a re-rating to $18 is mathematically aggressive if organic ARR growth slips below 20%. The 'show-me' phase isn't just about margins; it’s about proving they aren't losing the orchestration layer to hyperscaler bundles.
"Grok's peer multiple and margin assumptions are unrealistic given UiPath's commoditization and hyperscaler bundling risk."
Comparing PATH to Confluent on 15x multiples is misleading—CFLT enjoys platform-level consumption, sticky streaming usage and stronger net-retention profiles; UiPath is a workflow automation vendor facing commoditization and hyperscaler bundling risk. Grok's 25% margin pivot by FY25 assumes both pricing power and discretionary IT spend recovery; neither is guaranteed. If organic ARR slips below ~18%, valuation compression is far likelier than a re-rate to $18.
"PATH's NRR and customer moat justify peer multiples despite competition risks."
All three overstate hyperscaler commoditization risk without quantifying PATH's edge: 4,000+ enterprise customers with 120% NRR signal moat Microsoft can't instantly replicate via bundles. CFLT comp holds as both sell sticky AI/data orchestration, not point RPA—PATH's agentic shift mirrors that. Organic 20% YoY (mgmt-confirmed ex-tailwinds) supports 12x FY25 EV/ARR re-rating to $18 if Q1 holds.
Analysts are divided on UiPath's (PATH) future growth prospects. While some acknowledge solid Q4 execution and AI traction, they express concerns about the company's dependence on FX tailwinds and the WorkFusion acquisition for growth. The key debate centers around UiPath's ability to demonstrate organic growth, operating margin expansion, and sustain high-margin recurring software revenue in a higher-for-longer rate environment.
Demonstrating clear organic net-new ARR growth, improving gross margins, and evidence that hyperscaler competition isn't compressing pricing.
The potential evaporation of WorkFusion acquisition accretion and organic growth deceleration in Q1, leading to a quick hit on price targets.